Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Fig. 1

Immunohistochemical staining of serial prostatectomy sections showed presence of CD20+ B-cells cells aggregated in immune cell foci known as tertiary lymphoid structures (TLSs). a Representative AperioScope scanned image of anti-CD20 stained prostatectomy section counter-stained with hematoxylin. Tumor regions outlined by pathologist markings in blue, T = tumor, NT = non-tumor, ×10 magnification. b Box inset enlarged at ×200 magnification shows CD20+ B-cells stained brown in bright-field. c Post-deconvolution image of CD20 staining. After Imagescope deconvolution algorithm is run the stained color intensity is represented as image pixels with high intensity (brown), intermediate (orange) and low (yellow) staining intensity

Back to article page